Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Teva to present positive data for glatiramer acetate 40 mg/1 ml given three times weekly for relapsing-remitting MS
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Physiopathological Roles of p2x Receptors in the Central Nervous System.
Risk factors for rare diseases can be risky to define: PML and natalizumab.
A high-density screen for linkage in multiple sclerosis.
Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.
Clinical profile of malay children with optic neuritis.
Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs.
Imaging robust microglial activation after lipopolysaccharide administration in humans with PET.
The multiple sclerosis rating scale, revised (MSRS-R): Development, refinement, and psychometric validation using an online community.
GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of multiple sclerosis
Overcoming barriers in progressive multiple sclerosis research.
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.
Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis.
Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
Sanofi withdraws Campath in US and EU
Mitochondrial approaches for neuroprotection.
Guillain-Barré syndrome-like-onset neurosarcoidosis positive for immunoglobulin G anti-N-acetylgalactosaminyl-GD1a antibody.
Rescue Therapy Using Rituximab for Multiple Sclerosis.
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes.

Pages